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Abstract
Background: The objective of this study was to investigate whether the use of live attenuated varicella zoster virus
(VZV) MAV vaccination can efficiently induce VZV antibody production in naive rhesus monkeys as an approach to
prevent simian varicella virus (SVV) reactivation in animals immunosuppressed for transplantation studies.
Results: Clinically available human VZV vaccine was used to induce the production of anti-VZV antibodies in rhesus
monkeys. A vial of the vaccine was subcutaneously injected at 0 week, and the second and third vaccination was
performed at 5 and 6 weeks by intratracheal inoculation. The titer of anti-VZV IgG was assessed at 0, 2, 4, 6, and 7
weeks. At 2 weeks, 3/16 were seropositive for VZV IgG. At 6 weeks, 9/16 were shown to be seropositive. At 7 weeks,
16/16 were found to be seropositive.
Conclusions: The VZV vaccine via intratrachael inoculation was shown to induce VZV IgG humoral immunity in
rhesus monkeys and may be important immunosuppressed macaques for transplantation studies. Although the
humoral immunity produced is an important finding, further studies will be necessary to confirm possible
protection and it could protect probably against SVV infection in rhesus monkey.
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Background
Simian varicella virus (SVV) in Old World monkeys
causes epizootic erythematous disease, which is charac-
terized by fever, vesicular skin rash, hepatitis, and high
morbidity and mortality [1]. Outbreaks of SVV occur
sporadically in facilities housing nonhuman primates
and can result in a loss of valuable research animals [1].
When SVV infection outbreaks occur, prompt diagnosis
and antiviral treatment are important for patients at an
early time point. In nonhuman primate (NHP) trans-
plantation research involving the use of immunosup-
pressive drugs or in NHPs under immunocompromised
status, it is important to prevent the recurrence of latent
viruses in hosts that do not respond normally to infec-
tion following immunosuppression that produces a
weakened immune system. Human varicella-zoster virus
(VZV) infection shows clinical, pathological, and viro-
logic features similar to those of SVV infection [2]. VZV
infection, which does not induce clinical symptoms in
macaques, might be useful to protect monkeys against
SVV disease [3]. Thus, the objective of this study was to
investigate whether the use of live attenuated VZV MAV
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vaccination can efficiently induce VZV antibody produc-
tion in naive rhesus monkeys.
Results
Background history
R1 (ID of rhesus monkey number 1), an immunosup-
pressed rhesus monkey, for porcine islet transplantation
among 14 rhesus monkeys (8 naïve, 6 immunosup-
pressed), housed in Nonhuman Primate Research Center
at Seoul National University Hospital exhibited clinical
symptoms, such as systemic vesicular rash, fever, anorexia,
and vomiting (Table 1). SVV was suspected because of the
vesicular skin rash, and SVV viremia was confirmed by
qPCR. Anti-herpetic agent (ganciclovir 5mg/kg, IV, once
a day), antibiotics (cefazolin 30mg/kg, IV, twice a day),
NSAIDs (ibuprofen 30mg/kg, PO, in case of necessity),
TNF α blocker (adalimumab, 5mg/kg, SC, once), and an-
tiemetic (maropitant citrate, 1 mg/kg, SC, once a day)
were administered to treat SVV and to alleviate symp-
toms. Two days after the onset of symptoms, serum AST
and ALT levels were raised 10-fold relative to the upper
limit (AST: 46.7, ALT: 63.5) of normal [4]. The monkey
died 3 days after the onset of symptoms. Hemoperitoneum
and hepatic petechiae were observed on necropsy (Fig. 1).
The day after R1 displayed clinical symptoms, R2, R3, and
R4 developed systemic vesicular skin rashes, and SVV
viremia was also detected in these monkeys. Ganciclovir
and cefazolin, +/− ibuprofen +/− antiemetic were admin-
istered to treat SVV and to alleviate symptoms. R2, R3,
and R4 survived after receiving these treatments. The day
after R1 displayed clinical symptoms, the asymptomatic
monkeys received prophylactic ganciclovir. One week
after R1 became symptomatic, the asymptomatic
monkeys underwent qPCR testing for SVV, which
confirmed SVV viremia in R5 and R6; these monkeys,
however, remained asymptomatic. The absence of
symptoms might have resulted from the administra-
tion of prophylactic ganciclovir.
There were no complications related to subcutaneous
or intratracheal injection, such as pain, swelling, and
redness at the injection site and fever, irritability, drowsi-
ness, and rash by systemic reaction.

































+ Immunocompetence Ganciclovir IV SID
Cefazolin
Ibuprofen
Disappearance of rash 6 days after the onset of
symptoms
Recovery
R4 Vesicular skin rash
Vomiting
+ Immunocompetence Ganciclovir IV SID
Cefazolin
Maropitant citrate
Disappearance of rash 6 days after the onset of
symptoms
Recovery
R5 – + Immunosuppression for
islet TPL
Prophylactic use of ganciclovir SVV viremia detected but no symptoms by
prophylactic use of ganciclovir
R6 – + Immunocompetence Prophylactic use of ganciclovir SVV viremia detected but no symptoms by
prophylactic use of ganciclovir
R7 – – Immunosuppression for
islet TPL
Prophylactic use of ganciclovir
R8 – – Immunocompetence Prophylactic use of ganciclovir
R9 – – Immunosuppression for
islet TPL
Prophylactic use of ganciclovir
R10 – – Immunosuppression for
islet TPL
Prophylactic use of ganciclovir
R11 – – Immunocompetence Prophylactic use of ganciclovir
R12 – – Immunocompetence Prophylactic use of ganciclovir
R13 – – Immunocompetence Prophylactic use of ganciclovir
R14 – – Immunocompetence Prophylactic use of ganciclovir
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After subcutaneous injection of the vaccine, 3 out of
16 monkeys (18.7%) were seropositive at 2 weeks. At 6
weeks (1 week after the first intratracheal inoculation), 9
out of 16 monkeys (56.2%) were shown to be seroposi-
tive. At 7 weeks (1 week after the second intratracheal
inoculation), 16 out of 16 monkeys (100%) were found
to be seropositive (Fig. 2).
Longitudinal data of VZV IgG showed that four out of
five monkeys for which serum was available had VZV
IgG titers above cutoff value until after about 31 weeks,
especially R13, which had high VZV IgG titers until 55
weeks (Fig. 3).
Discussion
We found that SuduVax (VZV MAV strain), espe-
cially via intratracheal inoculation, was able to induce
VZV IgG production. Meyer et al. demonstrated a
lack of varicella and viral replication in either the
lungs or whole blood by wild type VZV intratracheal
inoculation in rhesus monkeys. All four rhesus mon-
keys generated an immune response characterized by
the generation of VZV-specific antibodies and T-cells
in their study. VZV-immune rhesus monkeys dis-
played no varicella rash and had lower SVV viral
loads as well as earlier and stronger humoral and cel-
lular immune responses than controls in the SVV
challenge [3]. Our data showed VZV vaccination of
monkeys generated a strong immune response with
VZV IgG induction suggesting it may provide protec-
tion against latent SVV reactivation and disease. Con-
firmation of protection, however, would require
further testing to prove if the humoral immunity pro-
duced is cross-protective, and if vaccination also in-
duces VZV cellular immunity and a high level of
protection against SVV challenge. If clinically avail-
able, the live attenuated form of the human VZV vac-
cine might may be useful for immunizing rhesus
monkeys and potentially providing protection against
Fig. 1 Images from necropsy on SVV-infected rhesus monkey. a Vesicular skin rash is shown on skin. b Hemoperitonium (arrow) due to
hemorrhage is observed in this severely infected monkey. c hepatic petechiae (arrowhead) by hemorrhage is observed
Fig. 2 VZA IgG monitoring data. The vaccine was subcutaneously injected at week 0 and administered by intratracheal inoculation at weeks 5
and 6. The dotted line indicates a positive cutoff value
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SVV disease. One strength of this study is the easy
availability of inoculation agent because VZV vaccine
is clinically available, but wild-type VZV is not.
The seropositivity of SuduVax (VZV MAV vaccine) by
subcutaneous inoculation in humans was shown to be 51
~ 69% in 1- to 6-year-olds [5]. Since SuduVax is adminis-
tered subcutaneously in humans, it was also administered
subcutaneously in rhesus monkeys. After subcutaneous
administration of SuduVax to rhesus monkeys, 18.7%
seropositivity was observed in this study, which was rela-
tively low compared to that of humans. A review of the lit-
erature confirmed that there was seropositivity in
monkeys when intratracheal inoculation of VZV was per-
formed [3], and the inoculation route of SuduVax was
changed to intratracheal inoculation. All subjects were
seropositive after two intratracheal inoculations.
There were a few limitations of this study. We were not
able to did not confirm that VZV IgG could neutralize the
SVV antigen due to the absence of the SVV antigen. The
SVV IgG level could not be measured because an ELISA
kit, which measures only SVV, was not available. A chal-
lenge test of SVV in VZV-vaccinated rhesus monkeys was
not performed due to lack of pathogenic SVV. In the fu-
ture, SVV can be obtained from leaders in the SVV field
for the needed challenge studies. However, because
various studies, especially Meyer et al.’s report [3], have
confirmed cross-reactive epitopes between SVV and VZV
[6–8], it might be enough to show only the seropositivity
of VZV IgG in rhesus monkeys. Although there were no
comparators, such as a subcutaneously administered
group and a intratracheal inoculation administered group,
at the group-setting stage, our vaccination strategy pro-
duced a strong positive VZV IgG response in all vacci-
nated animals and suggests further testing. This is because
the seropositivity of VZV IgG had to be achieved in a
short time to bring the monkey into our facility where the
SVV outbreak occurred.
We used 0.7 ml of SuduVax as an intratracheal inocu-
lation. This volume might be negligible in terms of safety
concerns. A typical volume of 1–2 mL/kg body weight
was safely used to avoid any potential coughing (> 2ml/
kg) and subsequent loss of instilled test material [9].
Conclusions
Our results showed that clinically available SuduVax was
able to induce VZV IgG production, especially after two
intratracheal inoculations at one-week intervals. These data
show a strong humoral immune response was produced by
VZV vaccination via intratracheal inoculation. They suggest
further efficacy testing against SVV challenge is needed to
confirm the use of VZV vaccination to protect against SVV
reactivation and disease in rhesus monkeys utilized for im-
munosuppressive and organ transplantation studies.
Methods
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee (IACUC) of the
Biomedical Research Institute at the Seoul National Uni-
versity Hospital, an AAALAC accredited facility (IACUC
approval number: 15–0297-C1A0).
After the SVV outbreak and follow-up in our NHP fa-
cility, we planned to immunize newly imported ma-
caques using clinically available human VZV vaccine.
SuduVax (VZV MAV strain; a live attenuated form,
Green Cross, Yongin, Korea) was used to immunize
Fig. 3 Long-term monitoring of VZV IgG titers in five monkeys. Four
out of five rhesus monkeys had VZV IgG titers above cutoff value for
at least 31 weeks
Fig. 4 Time schedule for SuduVax vaccination and VZV IgG titer monitoring. SC; subcutaneous injection. IT; intratracheal inoculation
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rhesus monkeys. Sixteen naïve female rhesus monkeys
(age: 3–5 years) were used. Sedation of the monkeys was
induced with medetomidine (0.2 mg/kg, IV) and keta-
mine (5 mg/kg, IV). The injection site was prepared
aseptically. A vial of the vaccine solution (0.7 ml, 1400
pfu) was subcutaneously injected at week 0 and adminis-
tered via intratracheal inoculation at week 5 and 6 due
to poor VZV IgG seropositive after 0 week subcutaneous
VZV inoculation. The trachea of the rhesus monkey was
grasped by the thumb and index finger of the nondomi-
nant hand. The needle was inserted into the trachea in a
30-degree cephalad or caudal orientation to the skin and
directed cranially or caudally after penetration of the an-
terior tracheal wall. Before inoculation, air was aspirated
to ensure that the needle was in the proper position.
The complications related to subcutaneous or intratra-
cheal injection were monitored by observer’s subjective
judgement for pain (hand touching on the injection sites,
the degree of coughing and screaming, decreased activ-
ity, and reduced food intake) and observer’s objective
judgement for swelling and redness at the injection site,
fever, and rash by systemic reaction. VZV IgG titers
were monitored at week 0, 2, 4, 6, and 7 (Fig. 4).
Two milliliters of blood was collected from the left sa-
phenous vein on weeks 0, 2, 4, 6, and 7. VZV IgG titers
were measured by chemiluminescent immunoassay (Li-
aison™ VZV IgG, DiaSorin S.p.A., Italy). VZV IgG titers
greater than 150 mIU/ml were considered seropositive
VZV IgG titers greater than 150 mIU/ml were considered
seropositive which is suggested by chemiluminescent im-
munoassay (Liaison™ VZV IgG, DiaSorin S.p.A., Italy) for
human VZV [10], cutoff value for rhesus monkey is not
existent because VZV is not the rhesus monkey’s disease.
To determine how the VZV IgG antibody titer waned
over time, we analyzed five monkeys among 16 at one of
three time points among 19, 23, 31, and 55 weeks.
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